1415 completed, 180 unknown, 89 recruiting, 74 terminated. 445 Phase 1, 367 Phase 2, 350 Not applicable, 298 Phase 3, 229 Phase 4.
Follow Mosquito-Borne Diseases: new trials by email Literature Review of Mosquito-Borne Diseases trials Research Report on Mosquito-Borne Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| OPTIMAL LEAP: Optimizing Dihydroartemisinin-Piperaquine IPTsc Intervals to Advance Learning, Executive Function, Attendance, and Antimalarial Resistance Surveillance in Kenyan Schoolchildren Monthly DP, Quarterly DP - Malaria, Asymptomatic Malaria | Phase 3 | Not yet recruiting | Indiana University | 1500 | 2028-01-01 | 2026-09-01 |
| Permethrin-Treated Baby Wraps for Malaria Prevention in Refugee Settings Factory-treated lesu, Soaked lesu, Untreated lesu - Malaria (Plasmodium Falciparum), Malaria Incidence | Not applicable | Not yet recruiting | University of North Carolina, Chapel Hill | 1350 | 2027-09-01 | 2026-10-29 |
| Against Chikungunya Virus and Neonatal Infection plasma transfusion : PC-CHIK-V - Chikungunya Virus Infection, Neonatal | Not applicable | Recruiting | Centre Hospitalier Universitaire de la Réunion | 60 | 2027-08-01 | 2026-09-15 |
| Study to Assess Safety and Clinical Responses With Coartem® Baby Dispersible Tablets in Paediatric Patients Weighing 2 to <5 kg With Uncomplicated Malaria Coartem® Baby - Malaria | Phase 4 | Not yet recruiting | Novartis Pharmaceuticals | 20 | 2027-06-18 | 2026-07-20 |
| Trial to Evaluate the Immunogenicity and Safety of the Co-administration of Live Attenuated Dengue and Chikungunya Vaccines Compared to Separate Administration in Adults Aged 18 to 59 Years. DENGUE: Dengue 1,2,3,4 (attenuated) vaccine CHIKUNGUNYA: Chikungunya (CHIKV) live attenuated vaccine (VLA1555), DENGUE: Dengue 1,2,3,4 (attenuated) vaccine, Chikungunya (CHIKV) live attenuated vaccine (VLA1555) - Dengue, Chikungunya | Phase 3 | Not yet recruiting | Butantan Institute | 900 | 2027-03-31 | 2026-07-16 |
| Challenge Trial of PfSPZ-LARC2 Vaccine in Burkina Faso PfSPZ-LARC2 Vaccine, PfSPZ Challenge, Normal Saline - Malaria (Plasmodium Falciparum) | Phase 1 | Not yet recruiting | Sanaria Inc. | 45 | 2027-03-01 | 2026-07-31 |
| Three-arm Cluster Randomised Control Trial Evaluation of Guardian Spatial Emanator as a Complimentary Vector Control Tool in Papua New Guinea Spatial emanator outdoor, Spatial emanator indoor - Malaria | Not applicable | Not yet recruiting | Macfarlane Burnet Institute for Medical Research and Public Health Ltd | 4350 | 2027-02-01 | 2026-11-03 |
| Phase I Study of VLPDEN-02 Dengue Vaccine in Healthy Adults VLPDEN-02 1.0 µg (0.25 µg of each VLP) + ALFQ adjuvant, VLPDEN-02 10 µg (2.5 µg of each VLP) + ALFQ adjuvant, VLPDEN-02 100 µg (25 µg of each VLP) + ALFQ adjuvant - Randomised Clinical Trial, Double Blind | Phase 1 | Not yet recruiting | VLP Therapeutics | 42 | 2027-01-04 | 2026-09-21 |
| Insecticide-Treated Baby Wraps for the Prevention of Malaria Permethrin-treated lesu, Etofenprox-treated lesu, Untreated lesu - Malaria (Plasmodium Falciparum), Malaria Incidence | Not applicable | Not yet recruiting | University of North Carolina, Chapel Hill | 1296 | 2027-01-01 | 2026-08-19 |
| Integrating the Guardian Spatial Emanator Within AVENIR II Spatial Emanator - Malaria | Not applicable | Not yet recruiting | University of California, San Francisco | 150000 | 2026-12-01 | 2026-07-22 |
| This is a Clinical Study to Assess Whether the Combination of SJ733 and Tafenoquine Will be a Safe and Rapidly Acting Anti-malarial for the Radical Cure of P. Vivax Malaria SJ733/TQ placebo, CQ/TQ Placebo, CQ/TQ - Malaria, Malaria Vivax | Phase 2 | Not yet recruiting | R. Kiplin Guy | 104 | 2026-12-01 | 2026-10-21 |
| Positron Emission Tomography and Organ-Specific Changes in Participants Co-Enrolled in NIH Studies of Plasmodium Vivax Controlled Human Malaria Infection 18F-fluorodeoxyglucose-positron emission tomography/computed tomography scan - Healthy Volunteer, Malaria | Not applicable | Not yet recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | 45 | 2026-11-08 | 2026-11-03 |
| Malaria CVD 36000; Gates INV090205 PfSPZ Challenge (NF54), Wearable Biosensor Devices, Placebo - Malaria (Plasmodium Falciparum) | Phase 1 | Not yet recruiting | University of Maryland, Baltimore | 32 | 2026-11-01 | 2026-09-09 |
| A Clinical Study of Piperaquine, Pyronaridine, and Artesunate Administered in Combination in Healthy Adults Piperaquine, Artesunate-pyronaridine (Pyramax), Piperaquine and artesunate-pyronaridine (Pyramax) - Malaria | Phase 1 | Not yet recruiting | University of Oxford | 24 | 2026-11-01 | 2026-08-05 |
| Investigating and Modelling the Natural History of Dengue in Hospitalised Patients to Improve Future Research Dengue | Not yet recruiting | Liverpool School of Tropical Medicine | 235 | 2026-11-01 | 2026-09-02 | |
| Humanitarian Evaluation of Spatial Emanators for Malaria Control Guardian™ long-lasting spatial emanators - Malaria Infection | Phase 4 | Not yet recruiting | The Mentor Initiative | 32584 | 2026-10-26 | 2026-10-21 |
| Ethiopian Antimalarial Therapeutic Efficacy Study 2026 Artemether-Lumefantrine + Primaquine and Chloroquine + Primaquine - Plasmodium Vivax Malaria Without Complication, Plasmodium Falciparum Malaria (Uncomplicated) | Not yet recruiting | Ethiopian Public Health Institute | 1200 | 2026-10-20 | 2026-09-25 | |
| Factors Influencing Adoption of a Novel Malaria Treatment in Côte d'Ivoire, Ghana, and Rwanda Malaria | Not yet recruiting | Novartis Pharmaceuticals | 184 | 2026-10-20 | 2026-10-27 | |
| Therapeutics for Moderate and Severe Dengue Placebo, Dexamethasone, N-Acetylcysteine - Dengue, Severe Dengue | Phase 3 | Not yet recruiting | Oxford University Clinical Research Unit, Vietnam | 8800 | 2026-10-01 | 2026-04-21 |
| Safety and Immunogenicity of the Recombinant Malaria Vaccines in Healthy Adults Aged 18-50 Years LYB014 low dose, LYB014 high dose, LYB017 low dose - Malaria Vaccine | Phase 1 | Not yet recruiting | Guangzhou Patronus Biotech Co., Ltd. | 72 | 2026-10-01 | 2026-10-22 |
Showing 20 of 1941. Sign in to see all of them.
Malaria (1137) · Malaria, Falciparum (451) · Dengue (275) · Malaria, Vivax (123) · Chikungunya Fever (88) · Zika Virus Infection (77) · Encephalitis, Japanese (72) · Anemia (67) · Severe Dengue (65) · Yellow Fever (44) · Elephantiasis, Filarial (41) · Fever (33) · HIV Infections (29) · Infections (29) · Diarrhea (25)
Vector Borne Diseases (1926) · Infections (1912) · Parasitic Diseases (1400) · Protozoan Infections (1374) · RNA Virus Infections (564) · Virus Diseases (556) · Arbovirus Infections (518) · Flaviviridae Infections (450) · Flavivirus Infections (441) · Hemorrhagic Fevers, Viral (322) · Malaria (244) · Pathological Conditions, Signs and Symptoms (189) · Hemic and Lymphatic Diseases (149) · Pathologic Processes (130)
Artemether, Lumefantrine Drug Combination (164) · fanasil, pyrimethamine drug combination (99) · Primaquine (92) · Chloroquine (89) · Artesunate (73) · Amodiaquine (57) · amodiaquine, artesunate drug combination (38) · Saline Solution (34) · tafenoquine (33) · Azithromycin (29) · Ivermectin (27) · Mefloquine (27) · pyronaridine tetraphosphate, artesunate drug combination (26) · Albendazole (25) · Blood Specimen Collection (23)
National Institute of Allergy and Infectious Diseases (NIAID) (180) · University of Oxford (135) · London School of Hygiene and Tropical Medicine (117) · U.S. Army Medical Research and Development Command (62) · Medicines for Malaria Venture (59) · GlaxoSmithKline (56) · Sanofi Pasteur, a Sanofi Company (49) · Centers for Disease Control and Prevention (37) · University of California, San Francisco (35) · Sanaria Inc. (29) · PATH (28) · Valneva Austria GmbH (28) · Institute of Tropical Medicine, Belgium (26) · Menzies School of Health Research (26) · Novartis Pharmaceuticals (26)
United States (266) · Burkina Faso (119) · Kenya (116) · Uganda (112) · Mali (104) · Thailand (95) · Tanzania (92) · United Kingdom (74) · Brazil (73) · Ghana (66) · Colombia (46) · Indonesia (44) · Vietnam (44) · Cambodia (43) · Malawi (43)
Anna Durbin, MD (30) · Patrick E Duffy, M.D. (14) · Grant Dorsey, MD, PhD (8) · Kassoum Kayentao, MD, MPH, PhD (7) · Salim Abdulla, MD, PhD (7) · Teun Bousema, PhD (7) · Francois Nosten, MD (6) · James McCarthy, Prof (6) · Rick M Fairhurst, M.D. (6)
PMID 39324693, PMID 40099800, PMID 23433102, PMID 34585740, PMID 25421474, PMID 26666916, PMID 39787798, PMID 42253092, PMID 26214039, PMID 28081133, PMID 29897841, PMID 33822015, PMID 39377226, PMID 11873261, PMID 22610930, PMID 26383952, PMID 28193647, PMID 28495354, PMID 29217375, PMID 31878895, PMID 31932368, PMID 32228663, PMID 33289099, PMID 35664997, PMID 35709798, PMID 35945599, PMID 36534705, PMID 37790581, PMID 38115002, PMID 38418982, PMID 39116904, PMID 40245769, PMID 41014333, PMID 41176969, PMID 42848323, PMID 10656038, PMID 18828899, PMID 19558654, PMID 19641203, PMID 20934459, PMID 21443960, PMID 21849081, PMID 22993389, PMID 23526949, PMID 23563266, PMID 23899517, PMID 23962071, PMID 24035558, PMID 24206649, PMID 24885993
2014 (8), 2019 (7), 2015 (5), 2016 (4), 2018 (4), R01HD068174 (4), R01AI141444 (3), 2023 (2), P01HD059454 (2), R01AI110478 (2), R01NS074409 (2), U01AI065683 (2), U01AI068632 (2), U01CI000211 (2), U19AI057266 (2)